参考文献/References:
[1] Perdoncin E, Zhang M, Riba A,et al.Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein Ⅱb/Ⅲa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium[J].Circ Cardiovasc Interv,2013,6(6):688-693.
[2] Warkentin TE, Greinacher A, Koster A.Bivalirudin[J].Thromb Haemost,2008,99(5): 830-839.
[3] Bittl JA, Chattman BR, Feit F, et al. Bivalidin versus heparin during coronary angioplasty for unstable or postinfarction angina:final report reanlysis of the Bivarudin Angioplasty Study[J].Am Heat J,2001,142(6):952-959.
[4] Linoff AM, Bittl JA, Harringon RA, et al.Bivarudin and provisional glycoprotein Ⅱb/Ⅲa blockade compared with heparin and planned glycoprotein Ⅱb/Ⅲa blockade during percutaneous coronary intervention:REPLACE-2 randomized trial[J].JAMA,2003,289(7):853-863.
[5] Feldman DN, Fakorede F, Minutello RM, et al.Efficacy of high-dose clopidogrel treatment(600 mg)less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes[J].Am J Cardiol,2010,105(3):323-332.
[6] Stone GW, Witzenbichler B, Guagliumi G, et al.Bivalirudin during primary PCI in acute myocardial infarction[J].N Engl J Med,2008,358(21):2218-2230.
[7] Mehran R, Lansky AJ, Witzenbiehler B, et al.Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction(HORIZ0NS-AMI):1year results of a randomized controlled trial[J].Lanct,2009,374(9696):1149-1159.
[8] Shah A, Feldman DN.Outcome of the HORIZONS-AMI trial bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty[J].Vasc Health Risk Manag,2012,8:115-123.
[9] Stone GW,Clayton T,Deliargyris EN, et al.Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding:The HORIZONS-AMI trial[J].J Am Coll Cardiol,2014,63(1):15-20.
[10] Zeymer U, van't Hof A, Adgey J,et al.Bivalirudin is superior to heparins alone with bailout GP Ⅱb/Ⅲa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention:a pre-specified analysis from the EUROMAX trial[J].Eur Heart J,2014,35(36):2460-2467.
[11] Steg PG, van't Hof A, Hamm CW, et al.Bivalirudin started during emergency transport for primary PCI[J].N Engl J Med,2013,369(23):2207-2217.
[12] Alexander W.Bivalirudin versus heparin:a fight far from finished?:efficacy, safety, and cost remain battlegrounds for the treatment of ST-segment elevation myocardial infarction[J].P T,2015,40(3):209-217.
[13] White H.Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction:the HERO-2 randomised trial[J].Lancet,2001,358(9296):1855-1863.
[14] Dang CH, Durkalski VL, Nappi JM, et al.Evaluation of treatment with direct thrombin inhibitors in patients with heparin induced thrombocytopenia[J].Pharmacotherapy,2006,26(4):461-468.
[15] Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patient with heparin induced thrombo cytopenia(ATBAT)study: main results[J].J Invasive Cardiol, 2003,15(11):611-616.
[16] 中华医学会心血管病学分会介入心脏病学.2012中国经皮冠状动脉介入治疗指南[J].中华心血管病杂志,2012,40:271-277.
[17] 柴栋,王睿,白楠,等.比伐卢定序贯给药在中国健康受试者中的药代、药效及安全性研究[J].中国临床药理学与治疗学,2014,19(7):785-788.
[18] 向定成.国产比伐卢定用于冠状动脉介入治疗术中抗凝的疗效和安全性评价[J].中国循环杂志,2011,26:331-334.
[19] 李军,杨小月,屈家祥,等.比伐卢定与替罗非班合用肝素在急诊经皮冠状动脉介入治疗中的疗效[J].中国老年学杂志,2014,14:3902-3904.
[20] 张萌,李娜,王蕾,等.比伐卢定在高龄急性冠状动脉综合征患者经皮冠状动脉介入治疗中的应用体会[J].中国介入心脏病学杂志,2014,5:318-321.
[21] 孙婧,田军,刘军翔,等.国产比伐卢定用于急性ST段抬高型心肌梗死患者急诊介入治疗术中的临床研究[J].中国循环杂志,2014,7:497-500.
[22] 赵榆华,傅宴,雷婷,等.替格瑞洛联合比伐卢定对STEMI急诊PCI无复流临床研究[J].现代医院,2014,8:30-32.
[23] 江龙,程晓曙,杨人强,等.比伐卢定对比肝素加血小板膜糖蛋白Ⅱb/Ⅲa受体抑制剂在PCI治疗中的安全性与有效性[J].临床心血管病杂志,2014,2:130-134.
[24] Keating FK, Dauerman HL, Whitaker DA, et al.Increased expression of platelet P-selectin and formation of platelet leukocyte aggregates in blood from patients treated with unfractionated heparin plus epptifibatide compared with bivalirudin[J].Thromb Res,2006,118(3):361-369.
[25] Roffi M,Patrono C, Collet JP, et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC)[J].Eur Heart J,2016,37(3):267-315.